Cargando…
Clozapine prescribing barriers in the management of treatment-resistant schizophrenia: A systematic review
BACKGROUND: Treatment-resistant schizophrenia is prevalent and difficult to manage, as patients fail multiple antipsychotic trials before being considered as treatment-resistant. Currently clozapine is the only Food and Drug Administration-approved pharmacotherapy for treatment-resistant schizophren...
Autores principales: | Baig, Anum Iqbal, Bazargan-Hejazi, Shahrzad, Ebrahim, Gul, Rodriguez-Lara, Jaziel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545051/ https://www.ncbi.nlm.nih.gov/pubmed/34766570 http://dx.doi.org/10.1097/MD.0000000000027694 |
Ejemplares similares
-
Schizophrenia hospitalization in the US 2005–2014: Examination of trends in demographics, length of stay, and cost
por: Chen, Ethan, et al.
Publicado: (2021) -
Psychotropic medication prescribing during the COVID-19 pandemic
por: Hirschtritt, Matthew E., et al.
Publicado: (2021) -
Achieving stable remission with maintenance electroconvulsive therapy in a patient with treatment-resistant schizophrenia: A case report
por: Moeller, Sebastian, et al.
Publicado: (2017) -
Effectiveness and safety of Baduanjin for schizophrenia: A protocol for systematic review and meta-analysis
por: Wu, Haiyuan, et al.
Publicado: (2022) -
Yoga and schizophrenia—a comprehensive assessment of neuroplasticity: Protocol for a single blind randomized controlled study of yoga in schizophrenia
por: Varambally, Shivarama, et al.
Publicado: (2019)